It is long established in the murine model system, as well as by clinical trials, that lethal CMV infections of the immunocompromised host can be prevented by AT of CMV-specific CD8 T cells, provided that the protective cells are administered early after infection [35–39]. The gene discussed is CD8A; the disease is cytomegalovirus infection.